MAUNA KEA TECHNOLOGIES Categorie -O- Aktie [WKN DE: A1JCLA / ISIN: FR0010609263]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu MAUNA KEA TECHNOLOGIES Categorie -O-

26.06.24		Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances (Businesswire)
15.12.20		Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the "Imaging and Robotics in Surgery (IRiS) Alliance” (Businesswire)
04.11.20		Mauna Kea Technologies Announces Two New Publications Demonstrating the Efficacy, Safety and Accuracy of Cellvizio® for Pancreatic Cyst Evaluation (Businesswire)
26.05.20		Mauna Kea Technologies: Cellvizio® Endorsed By the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) as a Safe and Effective Diagnostic Tool (Businesswire)
03.03.20		Mauna Kea Technologies Receives FDA Clearance And CE Marking For Its Next-Generation Cellvizio® Platform (Businesswire)
27.01.20		Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination (Businesswire)
08.01.20		Mauna Kea Technologies Announces Publication of Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions (Businesswire)
16.12.19		Mauna Kea Technologies Announces Strategic Equity Investment of €7.5 Million by Johnson & Johnson Innovation (Businesswire)
16.12.19		Mauna Kea Technologies Announces Strategic Equity Investment of €7.5 Million by Johnson & Johnson Innovation (Businesswire)
09.10.19		Mauna Kea Technologies Announces Positive Results on Needle-Based Endomicroscopy for Differentiating and Managing Pancreatic Cystic Lesions (Businesswire)
21.06.19		Mauna Kea Technologies SA (MKEA-FR): Reimbursement decision facilitates Cellvizio penetration in France (EQS Group)
26.04.19		Mauna Kea Technologies SA (MKEA-FR): Progressing toward long-term strategic growth (EQS Group)
09.04.19		Mauna Kea Technologies SA (MKEA-FR): FY2018 results validate move to consignment sales (EQS Group)
25.02.19		Mauna Kea Technologies Receives 510(k) Clearance for the Cellvizio® Needle-Based AQ-Flex™ 19 Confocal Miniprobe™ Enabling Peripheral Lung Nodule Targeting and Imaging (Businesswire)
21.02.19		Mauna Kea Technologies Provides an Update on Its Commercial Partnership Agreement for Urological Applications (Businesswire)
18.01.19		Mauna Kea Technologies SA (MKEA-FR): Q4 performance generating momentum for 2019 (EQS Group)
22.10.18		Mauna Kea Technologies SA (MKEA-FR): Q3 sales indicate growing momentum: (EQS Group)
03.10.18		Mauna Kea Technologies Announces First Published Report of Live "Tele-Cellvizio®” Utilization In Vivo between Surgeons and Remote Pathologists (Businesswire)
26.09.18		Mauna Kea Technologies Announces the Publication in Surgical Endoscopy of Positive Results from Large U.S. Prospective Multi-Center Clinical Trial on Detection of Barrett’s Esophagus with Cellvizio® (Businesswire)
25.09.18		Mauna Kea Technologies SA (MKEA-FR): H1 results reflect continued focus on the US (EQS Group)
08.08.18		Elanix Biotechnologies AG (ELN-DE): Updates from webcast include financial outlook (EQS Group)
03.08.18		Mauna Kea Technologies SA (MKEA-FR): Q2 reveals consignment model is gaining traction (EQS Group)
25.07.18		Mauna Kea Technologies Reports Second Quarter and First Half 2018 Sales (Businesswire)
12.07.18		Mauna Kea Technologies SA (MKEA-FR): Optical biopsies for increased diagnostic accuracy (EQS Group)
20.06.18		Mauna Kea Technologies Announces Positive Results from Mayo Clinic Sponsored Prospective Multi-Center Trial in Lung Transplant Patients (Businesswire)
31.05.18		Mauna Kea Technologies Announces 20 Presentations Highlighting Cellvizio’s® Clinical Value in Evaluating Inflammatory Bowel Disease and Pancreatic Cysts at Digestive Disease Week® 2018 (Businesswire)
24.05.18		Mauna Kea Technologies Obtains First Ever FDA Clearance for Applications of Cellvizio® Confocal Laser Endomicroscopy in Neurosurgery (Businesswire)
13.04.18		Mauna Kea Technologies’ Cellvizio® Demonstrates Superior Identification of Patients at Risk for Esophageal Cancer Compared to Current Diagnostic Standard (Businesswire)
03.04.18		In Vivo Confocal Laser Endomicroscopy with Cellvizio®, a Technology Developed by Mauna Kea Technologies Allows the Discovery of a Previously Unknown Human Structure, the Interstitium (Businesswire)
15.03.18		Cellvizio® Obtains Positive Assessment from the Korean National Evidence-based healthcare Collaborating Agency (NECA) (Businesswire)
31.01.18		Mauna Kea Technologies Reports Fourth Quarter and Full Year 2017 Sales (Businesswire)
15.01.18		Mauna Kea Technologies Appoints Experienced Healthcare Executive, Molly O’Neill, to Board of Directors (Businesswire)
05.01.18		Mauna Kea Technologies Announces its 2018 Financial Calendar (Businesswire)
18.12.17		New FDA Clearance Validates In Vivo, Real-Time "Identification of Cellular and Vascular Organization and Architecture” Using Cellvizio® (Businesswire)
01.12.17		Mauna Kea Technologies Renews Its Equity Financing Facility to Support Its Development (Businesswire)
16.11.17		Mauna Kea Technologies Announces Reimbursement Coverage for Cellvizio® in Croatia (Businesswire)
30.10.17		Mauna Kea Technologies: New CONTACT Study Analysis Demonstrates Cellvizio’s Ability to Improve the Management of Patients with Pancreatic Cysts (Businesswire)
19.10.17		Mauna Kea Technologies Reports Third Quarter 2017 Sales (Businesswire)
17.10.17		Mauna Kea Technologies Appoints Olivier Regnard as Deputy CEO And Chief Financial Officer (Businesswire)
11.10.17		Mauna Kea Technologies: New Economic Model Shows Significant Cost Savings When Using Cellvizio® to Ascertain Diagnosis of Benign Pancreatic Cysts (Businesswire)
09.10.17		Mauna Kea Technologies: Cellvizio® Now CE Marked for Use During Robotic-Assisted Surgery (Businesswire)
06.10.17		Mauna Kea Technologies Renews Its Equity Financing Facility to Support Its Development (Businesswire)
20.09.17		Mauna Kea Technologies Reports First Half 2017 Financial Results (Businesswire)
05.09.17		Mauna Kea Technologies: Cook Medical Announces Commercial Launch of Cellvizio for Urology (Businesswire)
31.08.17		Mauna Kea Technologies Announces Strong Presence of Cellvizio at the OESO 14th World Conference (Businesswire)
07.08.17		Mauna Kea Technologies Receives Specific U.S. FDA 510(K) Clearance for Use of Cellvizio During Robotic-Assisted Surgery (Businesswire)
07.08.17		Mauna Kea Technologies Receives Specific U.S. FDA 510(k) Clearance for Use of Cellvizio During Robotic-Assisted Surgery (Businesswire)
02.08.17		Mauna Kea Technologies Announces Peer-Reviewed Publication of Key Multicenter Randomized Controlled Trial Demonstrating Improved Early Stomach Cancer Detection with Cellvizio (Businesswire)
25.07.17		Mauna Kea Technologies Reports First Half 2017 Sales (Businesswire)
09.05.17		Mauna Kea Technologies Announces Strong Presence at Digestive Disease Week (DDW) 2017 Conference (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin bald bei 100.000 Dollar? MicroStrategy-CEO zeigt sich bullish - 100k-Party schon geplant

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

NEL ASA-Aktie fällt immer tiefer: Analysten sehen Risiken und raten zum Verkauf

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	24.11.2024 18:41
Kaufwert:	EUR
	Hinzufügen Speichern